CCCezar-Ivan Coliță

Cezar-Ivan Coliță

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cezar-Ivan Coliță has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Impact of Doping on Cognitive Abilities and Emotional Regulation in Elite Athletes -A Neurocognitive Perspective

    by Daniela Coliță, Leon Zăgrean, Cezar-Ivan Coliță, Dirk Hermann, Aurel Popa-Wagner

    The work analyzes the neurocognitive mechanisms underlying athletic performance, with emphasis on the impact of doping-particularly anabolic-androgenic steroids (AAS)-on cognitive abilities and emotional regulation in elite athletes. It clarifies the conceptual distinction between abilities and skills, referencing Fleishman’s classification and highlighting cognitive domains such as spatial orientation, attention, and memory. Key perceptual-cognitive abilities essential to high-level sports are discussed in relation to anticipation, reaction speed, and decision-making efficiency. Evidence from behavioral and neuroimaging studies indicates that prolonged AAS use leads to impairments in visuospatial memory, executive functioning, and attentional control, likely resulting from neurobiological alterations in prefrontal-limbic networks. Emotional regulation emerges as another crucial determinant of performance, with cognitive appraisal and reappraisal playing central roles in modulating affective responses under competitive pressure. By integrating cognitive, neurobiological, and emotional dimensions, the article contributes to a more comprehensive understanding of how performance-enhancing substances disrupt the neural and psychological mechanisms that support optimal athletic function and self-regulation.

  • Open Access

    Optimizing Chronotherapy in Psychiatric Care: The Impact of Circadian Rhythms on Medication Timing and Efficacy

    by Cezar-Ivan Colita, Dirk M. Hermann, Madalina Filfan, Daniela Colita, Thorsten R. Doepnner, Oana Tica, Daniela Glavan, Aurel Popa-Wagner

    In many medical settings, medications are typically administered in the morning or evening, aligning with patients’ daily routines. This practice does not stem from chronotherapy, which involves scheduling drug administration to enhance its effectiveness, but rather from the way clinical operations are structured. The timing of drug administration can significantly affect a medication’s effectiveness and side effects, with the impact varying by up to ten times based on circadian rhythms. Disorders such as major depression, bipolar disorder, and schizophrenia are linked to disruptions in these rhythms. Recent studies have found that circadian dysfunctions, including genetic and neurohumoral changes, underlie many psychiatric conditions. Issues such as an altered glucocorticoid rhythm due to impaired HPA axis function, disturbed melatonin balance, and sleep disturbances have been noted in psychotic disorders. Furthermore, mood disorders have been associated with changes in the expression of circadian rhythm genes such as Clock, Bmal1, and Per. Considering that the absorption, biodistribution, effects on target organs, half-life, metabolism, and elimination of drugs are all influenced by the body’s circadian rhythms, this narrative review explores the optimal timing of medication administration to maximize efficacy and minimize side effects in the treatment of psychiatric disorders. By closely monitoring circadian variations in cortisol, melatonin, and key clock genes, as well as by deepening our understanding of the metabolisms and pharmacokinetics of antipsychotic medications, we propose a chronotherapy approach for psychiatric patients that could significantly enhance patient care.


  • Open Access

    Induced Coma, Death, and Organ Transplantation: A Physiologic, Genetic, and Theological Perspective

    by Cezar-Ivan Coliță, Denissa-Greta Olaru, Daniela Coliță, Dirk M. Hermann, Eugen Coliță, Daniela Glavan, Aurel Popa-Wagner

    In the clinic, the death certificate is issued if brain electrical activity is no longer detectable. However, recent research has shown that in model organisms and humans, gene activity continues for at least 96 h postmortem. The discovery that many genes are still working up to 48 h after death questions our definition of death and has implications for organ transplants and forensics. If genes can be active up to 48 h after death, is the person technically still alive at that point? We discovered a very interesting parallel between genes that were upregulated in the brain after death and genes upregulated in the brains that were subjected to medically-induced coma, including transcripts involved in neurotransmission, proteasomal degradation, apoptosis, inflammation, and most interestingly, cancer. Since these genes are involved in cellular proliferation, their activation after death could represent the cellular reaction to escape mortality and raises the question of organ viability and genetics used for transplantation after death. One factor limiting the organ availability for transplantation is religious belief. However, more recently, organ donation for the benefit of humans in need has been seen as “posthumous giving of organs and tissues can be a manifestation of love spreading also to the other side of death”.


  • Open Access

    Therapeutic Use and Chronic Abuse of CNS Stimulants and Anabolic Drugs

    by Daniela Coliță, Cezar-Ivan Coliță, Dirk M. Hermann, Eugen Coliță, Thorsten R. Doeppner, Ion Udristoiu, Aurel Popa-Wagner

    The available evidence suggests that affective disorders, such as depression and anxiety, increase risk for accelerated cognitive decline and late-life dementia in aging individuals. Behavioral neuropsychology studies also showed that cognitive decline is a central feature of aging impacting the quality of life. Motor deficits are common after traumatic brain injuries and stroke, affect subjective well-being, and are linked with reduced quality of life. Currently, restorative therapies that target the brain directly to restore cognitive and motor tasks in aging and disease are available. However, the very same drugs used for therapeutic purposes are employed by athletes as stimulants either to increase performance for fame and financial rewards or as recreational drugs. Unfortunately, most of these drugs have severe side effects and pose a serious threat to the health of athletes. The use of performance-enhancing drugs by children and teenagers has increased tremendously due to the decrease in the age of players in competitive sports and the availability of various stimulants in many forms and shapes. Thus, doping may cause serious health-threatening conditions including, infertility, subdural hematomas, liver and kidney dysfunction, peripheral edema, cardiac hypertrophy, myocardial ischemia, thrombosis, and cardiovascular disease. In this review, we focus on the impact of doping on psychopathological disorders, cognition, and depression. Occasionally, we also refer to chronic use of therapeutic drugs to increase physical performance and highlight the underlying mechanisms. We conclude that raising awareness on the health risks of doping in sport for all shall promote an increased awareness for healthy lifestyles across all generations.